Eli Lilly takes early lead in weight loss drug race, BMO says
https://seekingalpha.com/news/4051344-eli-lilly-takes-lead-weight-loss-drug-race-bmo?source=feed_sector_healthcare
Dec 29, 2023 - Eli Lilly's (LLY) weight loss drug Zepbound is gaining market traction, challenging competitor Novo Nordisk (NVO). Read more here.
0
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
https://www.zacks.com/stock/news/2203352/eli-lilly-lly-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2203352
Dec 28, 2023 - The latest trading day saw Eli Lilly (LLY) settling at $580.85, representing a -0.11% change from its previous close.
0
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2195769/eli-lilly-lly-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2195769
Dec 08, 2023 - The latest trading day saw Eli Lilly (LLY) settling at $598.05, representing a +1.66% change from its previous close.
0
Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages
https://www.cnbc.com/2023/12/05/eli-lilly-weight-loss-drug-zepbound-available-at-us-pharmacies.html
Dec 05, 2023 - Eli Lilly's drug serves as an alternative to rival obesity drugs such as Wegovy that are still facing supply issues.
0